The new drug, Kisunla, has the potential to be a blockbuster for the company and generate billions in revenue. But despite ...
Alzheimer’s patients can temporarily lessen their symptoms with a recent FDA-approved drug that removes amyloid, or protein, ...
It's not a cure-- but it is a step in the right direction.This month-- a new medication for alzheimer's, called 'kinsul'a, ...
The US Food and Drug Administration (FDA) has approved Swiss company Positrigo’s NeuroLF brain positron emission tomography ...
The Food and Drug Administration last week approved donanemab, or Kisunla, an intravenous treatment for early stage Alzheimer ...
The Food and Drug Administration (FDA) recently approved a new drug from Eli Lilly to treat Alzheimer’s disease. Called ...
The Food and Drug Administration approved a new Eli Lilly drug this month that treats Alzheimer's disease. Kisunla is an IV ...
The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.
LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) announced that its primary treatment, Lomecel-B, has been granted Fast Track designation by the FDA only a week after being granted ...
The latest drug is showing promising results for adults with early Alzheimer's symptoms, mild cognitive impairment (MCI), and ...
The FDA approved Kisunla, known chemically as donanemab ... aren’t yet setup to prescribe the new plaque-targeting Alzheimer's drugs. First, doctors need to confirm that patients with dementia ...